Diagnostic and Management Challenges of Erosive Pustular Dermatosis of the Scalp: A Retrospective Study in a Greek Population - European Medical Journal
×

Browse

Diagnostic and Management Challenges of Erosive Pustular Dermatosis of the Scalp: A Retrospective Study in a Greek Population

|
3 Mins
EMJ Dermatology 9.1 Feature Image
Authors:
*Styliani Siskou,1,2 Aimilios Lallas,3,4 Konstantinos Theodoropoulos,5 Dimitrios Sgouros,5 Myrto Trakatelli,1 Aikaterini Patsatsi,1 Anastasia Trigoni,1 Magdalini Manoli,3,4 Chryssoula Papageorgiou,1,3 Konstantinos Liopyris,6 Alexandros Katoulis,5 Alexandros Stratigos,6 Dimitrios Ioannides,4 Elizabeth Lazaridou,1 Zoe Apalla1,3
Disclosure:

The authors have declared no conflicts of interest.

Acknowledgements:

Siskou and Lallas contributed equally to the preparation of this manuscript; Lazaridou and Apalla contributed equally in their role as senior authors.

Citation
EMJ Dermatol. ;9[1]:61-63. Abstract Review No. AR6.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

BACKGROUND

Erosive pustular dermatosis of the scalp (EPDS) is an inflammatory disorder of unknown aetiology, characterised by erosions, pustules, and crusts on a bed of atrophic skin.1-7 Risk factors include elderly age, actinic damage, androgenetic alopecia, and preceding trauma.1-7 It has long been considered a rare disease but recent reports suggest that it may be more frequent than previously thought.

MATERIALS AND METHODS

The authors conducted a retrospective, observational, multicentre study. They reviewed records of patients with clinically and histologically confirmed EPDS for baseline characteristics, time to diagnosis, treatments received, and outcomes. Treatment options included potent topical steroids (TS) under occlusion, topical calcineurin inhibitors (TCi) usually under occlusion, and systemic retinoids. A cycle of TS was defined as daily application for 2 weeks, followed by gradual de-escalation for a further 2 weeks. Follow-up visits were scheduled every 4 weeks. Outcomes were recorded as complete response (complete clinical resolution), partial response (30% or higher reduction of the affected area), progressive disease (20% or higher increase of the affected area), and stable disease. Deterioration and recurrence were defined as at least 20% loss of previous partial response and complete response, respectively. The statistical package STATA version 14.2 (StataCorp, College Station, Texas, USA) was used for data analysis. Twenty-four patients (22 males, two females) were included in the study. The majority were photodamaged (n=20/24 [83.3%]). The most commonly affected site was the vertex (n=19/24 [79.2%]). Twenty-two individuals (91.7%) had a positive non-melanoma skin cancer history, with actinic keratoses (AK) being the most frequently observed type (n=18/24 [75.0%]). Most patients had been treated with cryotherapy (n=17/24 [70.8%]) and imiquimod (n=14/24 [58.3%]).

RESULTS AND DISCUSSION

At first follow-up visit, from 22 patients treated with TS, 14 (63.6%) showed complete response, seven (31.8%) partial response, and one (4.6%) stable disease. After treatment cessation, the majority (78.3%) experienced a recurrence or deterioration at a median time of 8 weeks (interquartile range: 4–12 weeks; range: 2–16 weeks). Recurrence or deterioration was managed with either a TS cycle combined with 25 mg of acitretin daily (acitretin was continued after TS withdrawal as maintenance treatment); a TS cycle followed by TCi as maintenance treatment; or TCi in combination with 25 mg of acitretin, both in continuous application. New recurrences were observed in two out of nine patients (22.2%) that received acitretin, and in five out of seven patients (71.4%) that received TCi as maintenance (Figure 1)

Figure 1: Erosive pustular dermatosis of the scalp treatment flowchart. CR: complete response; PR: partial response; R: recurrence/deterioration; SD: stable disease.

The authors’ descriptive analysis of baseline characteristics of patients with EPDS conform with most recent publications.4,6,7,8 EPDS is diagnostically challenging due to a clinical overlap with other entities, including non-melanoma skin cancer, fungal/bacterial infections, bullous dermatoses, and folliculitis decalvans.4,5,9,10 Considering that it often develops in the background of field cancerisation, presence of actinic damage in the skin specimen may act as a misleading feature for the pathologist too, who may ultimately report the lesion as actinically damaged skin. The latter may result in further topical/destructive therapies that maintain the vicious circle of inflammation-impaired healing.

The management of EPDS is also challenging. Despite its responsiveness to TS,3,4,6,10 recurrence after treatment cessation is the rule.3,4,6,10 Prolonged use of TS cannot be considered since the latter promotes skin atrophy, which plays a key role in EPDS pathogenesis. Epidermis-preserving strategies, such as systemic retinoids or TCi, are desirable.

CONCLUSION

According to the authors’ results, systemic retinoids appear to be a superior form of maintenance treatment compared with TCi. Study limitations derive from its design, and the small sample size may create confounding and bias.

References
Tomasini C, Michelerio A. Erosive pustular dermatosis of the scalp: a neutrophilic folliculitis within the spectrum of neutrophilic dermatoses. J Am Acad Dermatol. 2019;81(2):527–33. Wilk M et al. Erosive pustular dermatosis of the scalp: reappraisal of an underrecognized entity. J Dtsch Dermatol Ges. 2018;16(1):15-9. Lee KH et al. Treatment of erosive pustular dermatosis: a systematic review of the literature. Int J Dermatol. 2020;59(7):770–86. Starace M et al. Erosive pustular dermatosis of the scalp: clinical, trichoscopic, and histopathologic features of 20 cases. J Am Acad Dermatol. 2017;76(6):1109-14. Yeh R et al. Erosive pustular dermatosis of the scalp – an Australian perspective: insights to aid clinical practice. Australas J Dermatol. 2019;60(4):e272-8. Junejo MH et al. Therapeutic options for erosive pustular dermatosis of the scalp: a systematic review. Br J Dermatol. 2021;184(1):25–33. Starace M et al. Erosive pustular dermatosis of the scalp: a multicentre study. J Eur Acad Dermatology Venereol. 2020;34(6):1348–54. Corradin MT et al. Erosive pustular dermatosis of the scalp induced by imiquimod. Case Rep Dermatol Med. 2012;2012:828749. Piccolo V et al. Erosive pustular dermatosis of the scalp: why do we miss it? Dermatology. 2019;235(5):390–5. Starace M et al. Erosive pustular dermatosis of the scalp: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:691–8.